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Abstract 
Manipulation of the gut microbiota presents a new opportunity to combat chronic diseases. 
Randomized controlled trials of probiotics suggest some associations with adiposity, lipids and 
insulin resistance, but no trials with hard outcomes have been conducted. We used separate-
sample Mendelian randomization to obtain estimates of the effects of 27 gut microbiota genera 
on ischemic heart disease, type 2 diabetes mellitus, adiposity, lipids and insulin resistance, based 
on summary data from CARDIoGRAAMplusC4D and other consortiums. Among 27 genera, a 1 
allele increase in single nucleotide polymorphisms related to higher Bifidobacterium was 
associated with lower risk of ischemic heart disease (odds ratio 0.977, 95% confidence interval 
(CI) 0.96, 1.00, P=0.04), 0.011 standard deviation lower in body mass index (95% CI -0.017, -
0.005) but 0.026 standard deviation higher in low-density lipoprotein cholesterol (95% CI 0.019, 
0.033), which, however, were not robust to exclusion of potential pleiotropy. We also identified 
Acidaminococcus, Aggregatibacter, Anaerostipes, Blautia, Desulfovibrio, Dorea and 
Faecalibacterium as nominally associated with type 2 diabetes mellitus or other risk factors. 
Results from our study indicate that these 8 genera should be given priority in future search 
relating the gut microbiome for new means to prevent and treat leading causes of global 
morbidity and mortality. 
 
Keywords: gut microbiota, Mendelian randomization, ischemic heart disease, type 2 diabetes 
mellitus 
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The human intestine is increasingly understood as harboring a complex community of trillions of 
bacteria having symbiotic relations with their host and thereby potentially affecting risk of major 
non-communicable diseases. In animals and humans, a microbiota-dependent metabolite, 
trimethylamine-N-oxide, is a predictor of cardiovascular disease 1, 2, suggesting a potential link 
between the gut microbiota and cardiovascular disease. Additionally, the gut microbiota may 
shape host metabolism, affecting the development of type 2 diabetes mellitus (T2DM) and 
adiposity 3, which are important risk factors for cardiovascular disease.  
Observationally some gut microbiota taxa have been associated with cardiovascular disease, its 
subtypes or risk factors. A small case-control study (n=128) found order Lactobacillales 
positively associated with ischemic heart disease (IHD) and phylum Bacteroidetes inversely 
associated with IHD 4. A systematic review implicated several species/genera in T2DM, but was 
only based on four small heterogeneous observational studies (total n=576) 5. A recent case-
control study (n=223) observed lower Bacteroides thetaiotaomicron in the obese 6. Lactobacillus 
reuteri was reported positively associated with body mass index (BMI), and Bifidobacterium 
animals, Methanobrevibacter smithii and Escherichia coli were negatively associated with BMI 
in 263 people (51% obese) 7. In a cohort of 893 adults 34 taxa were associated with BMI and 
lipids, at a false discovery rate of 0.05 8. Prevotella copri and Bacteroides vulgatus were the 
main species associated with homeostatic model assessment insulin resistance (HOMA-IR) in 
277 people without diabetes (58% obese) 9. However, these small observational studies are 
difficult to interpret because they are open to confounding by socially patterned factors, such as 
diet, which may affect the gut microbiota and health, and to changes in the gut microbiota in 
response to ill-health. 
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Meta-analyses of small randomized controlled trials (RCTs) suggested microbiota manipulation 
through probiotics, usually of Lactobacillus or Bifidobacterium, had a protective effect on 
adiposity 10, 11 but mixed effects on high-density lipoprotein cholesterol (HDL-C), low-density 
lipoprotein cholesterol (LDL-C) 12-14, and HOMA-IR 12, 13 with high heterogeneity. No RCT of 
probiotics with disease end-points has been conducted. Moreover, large meta-analyses of RCTs 
of antibiotics testing the role of antibiotic therapy in cardiovascular disease, which almost 
certainly changed the gut microbiome, did not affect cardiovascular disease mortality 15, 16. No 
effect of vancomycin on HOMA-IR was found in an RCT of 57 obese, pre-diabetic men 17. 
However, the exact effect of the antibiotics used in these RCTs on individual gut microbiota taxa 
is unknown, so at most they suggest we cannot rule out a role for a specific taxon.  
In the absence of definitive studies giving the causal effects of specific gut microbiota taxa on 
IHD, T2DM, and their risk factors, comparing risk by genetically predicted taxon abundance, i.e. 
Mendelian randomization (MR), provides an alternative means of assessing the role of the gut 
microbiota in major non-communicable diseases. Since genetic endowment is randomly 
allocated at conception, analogous to the randomization in RCTs, MR is less vulnerable to 
confounding than observational studies 18. To our knowledge, no MR study of the gut microbiota 
has been conducted. We conducted a separate-sample MR study based on genome-wide 
association studies (GWAS) predicting 27 genera applied to large extensively genotyped case-
control studies of IHD and T2DM, and cross-sectional studies of adiposity, lipids and HOMA-IR 
to identify agnostically genera associated with these health outcomes.   
 
METHODS 
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Genetically predicted gut microbiota genera 
Genetic predictors of 27 genera at genome-wide significance (P < 5×10-8) were obtained from all 
currently available GWAS of stool samples in humans 19-23. Highly correlated single nucleotide 
polymorphisms (SNPs) (r2 ≥0.8) were discarded based on larger P with correlations taken from 
Ensembl 24 (1000 Genomes: phase_3 among Europeans) and SNP Annotation and Proxy Search 
25 (1000 Genomes Pilot 1 catalog). If a SNP was not available for an outcome, a highly 
correlated proxy SNP (r2 ≥ 0.8) was used instead, if available. We also replaced rs892244 
(Cadherin 13 (CDH13)), because of a discrepancy between the major allele given in the GWAS 
22 and Ensembl 24, with rs8063330 (CDH13), which is highly correlated with rs892244 (r2 =  
0.941) and was associated the same genus (P = 2.68×10-7) in the same GWAS 22. We checked 
the phenotypes of selected SNPs using comprehensive genotype-to-phenotype cross-references, 
i.e. Ensembl 24 and GWAS Catalog 26, and repeated the analysis with potentially pleiotropic 
SNPs (rs1446585 (RNA, U6 small nuclear 512, pseudogene) and rs4988235 (minichromosome 
maintenance complex component 6)) excluded. We calculated SNP-specific F-statistics as a 
quotient of squared SNP-genus association and its variance 27. A mean F-statistic for each genus 
(predicted by uncorrelated SNPs) was approximated as an average of the corresponding quotients 
27.  
 
Genetically predicted IHD, T2DM and their risk factors  
CARDIoGRAMplusC4D 1000 Genomes is a case (n=60,801)-control (n=123,504) study of IHD, 
extensively genotyped using the 1000 Genomes phase 1v3 training set, largely of people of 
European descent (77%) 28. As sensitivity analysis, we also used CARDIoGRAMplusC4D 
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Metabochip, (63,746 cases and 130,681 controls) largely of European descent imputed to 
HapMap 2 29, which overlaps with 1000 Genomes (57.5% cases, 40.1% controls). If SNPs were 
not available in CARDIoGRAMplusC4D Metabochip, genetic associations were obtained from 
the more extensively genotyped subset in CARDIoGRAM, (22,233 cases, 64,762 controls) of 
European descent 30. All three studies were age- and sex-adjusted. 
Genetic associations with T2DM, adjusted for age and sex, were from DIAbetes Genetics 
Replication And Meta-analysis case (n=34,380)-control (n=114,981) study 31. Genetic 
associations with adiposity were from The Genetic Investigation of Anthropometric Traits with 
BMI and waist-hip ratio (standard deviation) for 332,154 and 210,222 people of European 
descent respectively, adjusted for age, age2, and study-specific covariates 32. Genetic associations 
with HDL-C and LDL-C (standard deviation), adjusted for age, age2 and sex, were obtained from 
the Global Lipids Genetic Consortium Results, of up to 188,577 participants of European descent 
and 7,898 participants of non-European descent 33. Genetic associations with HOMA-IR (log-
transformed) were from the Meta-Analyses of Glucose and Insulin-related traits Consortium of 
46,186 people of European descent 34.  
 
Statistical analysis 
Estimates of the association of each genus with IHD and its risk factors were obtained by 
combining SNP-specific Wald estimates 35 using inverse variance weighting with fixed effects 
for uncorrelated SNPs and weighted generalized linear regression, considering correlations 
between SNPs (Web Appendix 1) 36. Variance of a Wald estimate was obtained from Fieller’s 
theorem 37 or an approximation if the variance for SNP on exposure was not given 38. When 
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different GWAS used incompatible microbiota units for SNPs predicting the same genera, we 
used SNP-outcome associations (Web Table 1) 39. If a genus was predicted by >3 uncorrelated 
SNPs, MR-Egger and weighted median methods were used as sensitivity analyses. MR-Egger 
checks for unknown horizontal pleiotropy indicated by a non-zero intercept 40, with its “No 
Measurement Error” assumption tested by I2 27. If I2 was less than 90%, we performed simulation 
extrapolation to adjust for this violation 27. A weighted median estimate is robust to 50% of the 
SNPs being invalid genetic instruments 40. Bonferroni correction was used to adjust for multiple 
comparisons among genera within each outcome, giving a cutoff of 0.00185 for IHD in 
CARDIoGRAMplusC4D 1000 Genomes and 0.002 for the other outcomes. Given the overlap of 
participants between the two IHD case-control studies, we also combined their estimates 
accounting for this overlap using the Lin and Sullivan approach 41. All statistical analyses were 
conducted using Stata version 13.1 (StataCorp LP, College Station, TX) and R version 3.2.5 (R 
Foundation for Statistical Computing, Vienna, Austria). This study used publicly available 
summary data. Therefore, no ethical approval was required.  
 
RESULTS 
Five GWAS of the gut microbiota were identified, giving 94 SNPs related to 27 gut microbiota 
genera at genome-wide significance. 16S rRNA gene sequencing was used in four studies 19-22 
and metagenomics sequencing in one study 23. In UK Twins (n=2,731, 11% men, age range 19 to 
89 years) 13 SNPs predicted 7 genera (Box-Cox transformed relative abundance) 19. In 1,812 
people from Germany (46% men, age range 18 to 83 years) 5 SNPs predicted 4 genera in a 
generalized linear model with a negative binomial distribution and log link 20. In 1,561 healthy 
participants of European descent (45% men, age range 6 to 35 years) 29 SNPs predicted 17 
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genera (log-transformed relative abundance) 21. In 127 Hutterites (38% men, age range 6 to 92 
years), of European descent, rs2630788 (zinc finger protein 385D) and rs892244 (CDH13) 
predicted Anaerostipes and Bifidobacterium (normalized relative abundance) respectively 22. 
Finally, in 1,514 participants (42% men, age range 18 to 84 years) from Dutch cohorts 45 SNPs 
predicted 5 genera (normalized abundance) 23. We excluded 37 highly correlated SNPs. The 
remaining 57 SNPs from 55 genes were used in this study (Web Tables 2, 3) to predict 27 
genera: Acidaminococcus, Acinetobacter, Aggregatibacter, Anaerostipes, Atopobium, 
Bacteroides, Bifidobacterium, Blautia, Coprococcus, Desulfovibrio, Dialister, Dorea, 
Eggerthella, Escherichia, Eubacterium, Faecalibacterium, Lachnospira, Lactobacillus, 
Leuconostoc, Megamonas, Mogibacterium, Oscillibacter, Oscillospira, Pseudobutyrivibrio, 
Roseburia, Slackia and Weissella. All available F-statistics were >10 (Web Table 2). 
Bifidobacterium, based on 3 SNPs from different GWAS, was associated with lower IHD in the 
two CARDIoGRAMplusC4D studies combined, accounting for their overlap (Table 1, Web 
Figure 1c), although this association was not evident in CARDIoGRAMplusC4D 1000 Genomes 
(Web Figure 1a). Bifidobacterium was also associated with lower BMI (Table 1, Web Figure 1e), 
higher HDL-C (Table 1, Web Figure 1g), higher LDL-C (Table 1, Web Figure 1h), and lower 
HOMA-IR (Table 1, Web Figure 1i). Only the associations with BMI and LDL-C were robust to 
Bonferroni correction (Table 1). However, after the exclusion of pleiotropic SNPs 
Bifidobacterium was not associated with any outcome considered (Web Table 4). 
We further identified 7 genera nominally associated with IHD risk factors. Acidaminococcus, 
based on 5 uncorrelated SNPs from the same GWAS, was associated with higher HDL-C (Table 
1, Web Figure 1g). Sensitivity analysis using MR-Egger and weighted-median gave similar 
estimates (Web Table 5). Aggregatibacter, based on 1 SNP, was associated with higher HDL-C 
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(Table 1, Web Figure 1g). Anaerostipes, based on 2 SNPs from different GWAS, was associated 
with lower T2DM (Table 1, Web Figure 1d). Blautia, based on 6 SNPs from different SNPs, was 
associated with lower LDL-C (Table 1, Web Figure 1h). Desulfovibrio, based on 2 uncorrelated 
SNPs from the same GWAS, and Dorea, based on 1 SNP, were associated with higher HOMA-
IR (Table 1, Web Figure 1). Faecalibacterium, based on 4 SNPs from different GWAS, was 
associated with lower waist-hip ratio (Table 1, Web Figure 1f). However, none of these 
associations were robust to Bonferroni correction (Table 1).  
Additionally, Lachnospira, based on 1 SNP, was associated with higher IHD in 
CARDIoGRAMplusC4D Metabochip (Table 1, Web Figure 1b), but not in 
CARDIoGRAMplusC4D 1000 Genomes (Web Figure 1a), or in the two 
CARDIoGRAMplusC4D studies combined accounting for their overlap (Web Figure 1c). No 
associations were found for the other 18 genera, namely Acinetobacter, Atopobium, Bacteroides, 
Coprococcus, Dialister, Eggerthella, Escherichia, Eubacterium, Lactobacillus, Leuconostoc, 
Megamonas, Mogibacterium, Oscillibacter, Oscillospira, Pseudobutyrivibrio, Roseburia, Slackia 
and Weissella (Web Figure 1). 
 
DISCUSSION 
In what is to our knowledge the first MR study relating gut microbiota to IHD and its risk 
factors, we found some preliminary indications of beneficial associations of Bifidobacterium 
with BMI, HDL-C and HOMA-IR. We also found some nominal associations of 
Acidaminococcus, Aggregatibacter, Anaerostipes, Blautia, Desulfovibrio, Dorea and 
Faecalibacterium with modestly lower risk of T2DM, less adiposity, more beneficial lipid 
10 
 
profiles or higher HOMA-IR. Associations of the other genera considered with these outcomes 
appeared less likely.  
Our study has some consistency with an observational study showing no robust association of 
genera Bacteroides, Blautia, Coprococcus, Eggerthella or Lachnospira with BMI, HDL-C or 
LDL-C 8, although we also found Blautia nominally associated with lower LDL-C. However, our 
study is less consistent with a small case-control study showing order Lactobacillales positively 
and phylum Bacteroidetes negatively associated with IHD but Bifidobacterium unrelated to IHD 
4, 42. In fact, observational studies of the gut microbiota are probably susceptible to unmeasured 
confounding, by factors such as diet and health status. Our study also has some consistency with 
meta-analyses of RCTs showing beneficial effects of probiotics, typically including 
Bifidobacterium, on BMI 10, 11, HDL-C 12, 13 and HOMA-IR 13, although associations with HDL-
C and HOMA-IR in our study were less evident after correction for multiple comparisons. 
However, these meta-analyses of RCTs may be vulnerable to biases from small sample sizes 
(ranging from 234 to 1,931) and/or high heterogeneity (I2 ranging from 0% to 92%) 10-13. In 
addition, some RCTs included in these meta-analyses suggest a role for probiotics including 
Lactobacillus 10-12, but we found no associations for Lactobacillus, perhaps because the gut 
microbiota acts synergistically 43, so that the effect of a particular mix may be different from the 
effect of its constituent parts. A large well-conducted RCT in a well-characterized population 
using probiotics capsules containing sole species may provide further clarification. Finally, our 
study has some consistency with meta-analyses of RCTs showing little association of antibiotics 
with IHD 15, 16, because these RCTs likely changed the gut microbiota but did not affect 
cardiovascular disease mortality. RCTs targeting Bifidobacterium (or more generally 
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investigations of exact effects of various antibiotics on specific gut microbiota taxa) might 
provide further evidence for IHD prevention. 
Many potential pathways linking specific gut microbiota to non-communicable diseases have 
been identified. A possible pathway linking gut microbiota to IHD is via dietary choline (from 
shrimps and eggs) or dietary carnitine (from meat) to trimethylamine and trimethylamine-N-
oxide 44. However, the role of specific taxa in trimethylamine production is not entirely clear 45 
and we did not identify any genus robustly associated with IHD. Host metabolites linking gut 
microbiota to T2DM/metabolic syndrome may exist. Short-chain fatty acids are generated by 
many gut microbiota genera, such as Anaerostipes, Bacteroides, Bifidobacterium, Blautia, 
Clostridium, Dialister, Prevotella, Roseburia, Salmonella and Streptococcus, from fermentation 
of dietary fiber and may have beneficial metabolic effects for the host 46. Meta-analysis of RCTs 
showed dietary fiber reduces LDL-C 47, and we further identified that Blautia, possibly fueled by 
dietary fiber 46, might provide the mechanism. Whether any beneficial effect of Blautia on LDL-
C is mediated by short-chain fatty acids would be informed by RCTs investigating the role of 
Blautia in short-chain fatty acids production. Branched-chain amino acids have essential 
signaling functions, may be synthesized by Prevotella copri and Bacteroides vulgatus 9, and 
were positively associated with T2DM and BMI 48, but not with any marker of glucose 
metabolism 48, 49. Correspondingly, we did not find Bacteroides associated with HOMA-IR. A 
recent observational study found several Bacteroides species inversely correlated with branched-
chain amino acids 6, but the role of these species in the biosynthesis of branched-chain amino 
acids needs to be further confirmed in humans. Notably, lactase persistence alleles predicting 
lower Bifidobacterium abundance have been associated with higher milk drinking 50 and with 
anthropometric traits 24, 26. Since lactose fuels Bifidobacterium in the human intestine 19, 
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Bifidobacterium may have more of an effect in populations who drink milk despite lactose 
intolerance. Given the role of Bifidobacterium is difficult to distinguish from that of lactase 
persistence in people of European descent, replication in a population without lactase 
persistence, such as East Asians, would be helpful. Bidirectional MR studies to assess whether 
IHD and its risk factors influence the gut microbiota might also be informative. More generally, 
this study raises the question as to whether the search for a healthy diet should focus on the effect 
of foods and their constituents on health or their many mechanisms, including the gut microbiota. 
In the era of “big data”, taking advantage of GWAS and large publicly available data with 
extensive genotyping enables a cost-efficient MR study 36. Nevertheless, limitations regarding 
MR and gut microbiota exist. First, MR has stringent assumptions. Although we selected SNPs 
uniquely associated with 27 genera at genome-wide significance, few of them achieved study-
wide significance, and thus we could not fully rule out the possibility of weak instrument bias. 
However, our F-statistics suggest little evidence of that 51. A post-hoc power calculation 52 
assuming a statistical confidence level of 0.05, an R2 equaling genus heritability and an effect 
size shown in Table 1 suggested power of greater than 80% for the associations of 
Bifidobacterium with BMI and LDL-C, but less than 80% for weaker associations. As such 
larger MR studies are necessary, to distinguish associations with small effect sizes from null 
associations. In addition, some SNPs identified in one GWAS were not replicated in others due 
to low variance in the corresponding genera or different SNP selections. Publicly releasing all 
available individual GWAS, or their summary, would be helpful, as would further GWAS in 
larger more homogenous samples. More generally, our study did not consider associations 
between the 27 genera or all bacterial taxa. For example, family Bifidobacteria is inversely 
associated with species Escherichia coli 53. Cross-phenotype association analysis 54 combining 
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GWAS may help identify more accurate genetic instruments and clarify our MR estimates, when 
data is available. Residual pleiotropy is difficult to exclude, as functions of most SNPs have not 
been comprehensively identified; use of MR-Egger and a weighted median to identify pleiotropy 
statistically was restricted by the limited number of genetic instruments. Confounding by 
population stratification is possible. However, all five GWAS concerned participants of 
European descent 19-23 and the genetic associations with IHD and its risk factors are all from 
studies conducted largely in people of European descent with genomic control 28-34. Second, 
canalization may buffer the genetic effects of gut microbiota, so its manipulation might not have 
the same effect as that genetically predicted. However, whether the relevance of canalization 
exists is unknown. Third, winner’s curse may bias our MR estimates, but its direction is 
ambiguous 51. Finally, selection bias may influence our MR estimates, where genetic associations 
are obtained from studies in older people 55 or otherwise condition on genetic make-up and 
exposure or outcome. However, they did not condition one phenotype on another, reducing the 
risk of bias 56. 
In terms of specific limitations of applying MR to gut microbiota, the studies used to identify 
genetic predictors of Bacteroides, Bifidobacterium, Coprococcus, Dorea, Eggerthella and 
Faecalibacterium and to identify their associations with adiposity and lipids overlapped slightly 
because of the participants in the TwinsUK study 57. However, they only form a very small 
proportion of these studies which is unlikely to create a bias 58 and separate-sample MR reduces 
the risk of chance associations generated by the underlying data structure in a one-sample MR 59. 
Use of separate samples also means that possible non-linear associations, subgroup analysis by 
age and sex, and diet-microbiome interactions could not be tested 60, but causal effects should be 
generally consistent. Second, the 16S rRNA gene sequencing used by most microbiota GWAS 
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usually only permits resolution at genus level rather than at a more specific level, so we cannot 
rule out the possibility that some specific species or strains are associated with IHD or its risk 
factors. Additionally, we cannot rule out the possibility that a ratio of two taxa or dysbiosis of 
gut microbiota contributes to cardiovascular disease or its risk factors as suggested by some 
observational studies 8, 61, 62, although the ratio of Bacteroidetes to Firmicutes is not consistently 
associated with adiposity in humans 63. Fourth, gut microbiota may also be influenced by other 
factors, such as the time/season of stool sampling, which may decrease the variance explained by 
genetics. However, gut microbiota is thought to have temporal stability especially after early 
childhood, and the dominant force in determining its composition is long-term dietary habits 64. 
As such, our findings may be more relevant to the effects of gut microbiota from adolescence or 
adulthood. Our study is also limited by the current understanding of the gut microbiota. A 
hypothesis driven study testing epidemiologically established associations would have been 
preferable, but was precluded by the lack of knowledge as to the function of each constituent of 
the microbiome and by the lack of large epidemiological studies. In addition, differences in 
statistical methods between gut microbiota GWAS made the units hard to interpret. As such, we 
presented results per allele for Bifidobacterium, Blautia, Anaerostipes, Bacteroides, Dialister and 
Faecalibacterium, so these estimates are best understood as providing direction and we could not 
completely rule in/out their causal effects on the outcomes considered 65. Finally, our findings 
mainly concern Europeans. Gut microbiota may vary between populations 66, so replication in 
different populations are needed. Replication with functionally relevant genetic prediction of gut 
microbiota would also be helpful.  
Our study generates the hypothesis that Acinetobacter, Atopobium, Bacteroides, Coprococcus, 
Dialister, Eggerthella, Escherichia, Eubacterium, Lachnospira, Lactobacillus, Leuconostoc, 
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Megamonas, Mogibacterium, Oscillibacter, Oscillospira, Pseudobutyrivibrio, Roseburia, Slackia 
and Weissella are unlikely to have a major causal association with IHD or T2DM, and so might 
not warrant extensive testing. Our study also raises the possibility of a beneficial association of 
Bifidobacterium with IHD, adiposity, HDL-C and HOMA-IR, as well as associations of 
Acidaminococcus, Aggregatibacter, Anaerostipes, Blautia, Desulfovibrio, Dorea and 
Faecalibacterium with cardiovascular disease risk factors, suggesting these might be the focus of 
future investigation. Further MR studies using multiple robust instruments are needed to confirm 
these results given our study was limited by single genetic instruments for some genera. 
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Table 1. Associations of Selected Genetically Predicted Gut Microbiota Genera with IHD, T2DM, Adiposity, Lipids and HOMA-IR 
Genus Unit of exposure Outcome Combined 
Estimatea 
95% confidence 
interval 
P 
Acidaminococcus per relative abundance (log10) HDL-C (SD) 0.001
b 0.0003, 0.002 0.006 
Aggregatibacter per relative abundance (log10) HDL-C (SD) 0.039 0.002, 0.075 0.038 
Anaerostipes per allele T2DM 0.960 0.926, 0.996 0.032 
Bifidobacterium per allele IHD Metabochip 0.959 0.943, 0.976 1.7×10˗6 
  IHD two studies combined 0.985 0.971, 1.000 0.043 
  Body mass index (SD) ˗0.011 ˗0.017, ˗0.005 1.6×10˗4 
  HDL-C (SD) 0.010 0.003, 0.017 0.004 
  LDL-C (SD) 0.026 0.019, 0.033 4.3×10˗12 
  HOMA-IR (log-transformed) ˗0.008 ˗0.015, ˗0.001 0.022 
Blautia per allele LDL-C (SD) ˗0.008 ˗0.014, ˗0.002 0.011 
Desulfovibrio per relative abundance (log10) HOMA-IR (log-transformed) 0.007 0.0001, 0.014 0.046 
Dorea per relative abundance (Box-Cox 
transformed) 
HOMA-IR (log-transformed) 0.024 0.005, 0.043 0.013 
Faecalibacterium per allele Waist-hip ratio (SD) ˗0.009 ˗0.016, ˗0.003 0.008 
Lachnospira per relative abundance (log10) IHD Metabochip 1.095 1.001, 1.197 0.046 
Abbreviations: HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostatic model assessment insulin resistance; IHD, 
ischemic heart disease; LDL-C, low-density lipoprotein cholesterol; SD, standard deviation; T2DM, type 2 diabetes mellitus.  
a Odds ratio for IHD and T2DM; β for other outcomes. 
b 0.001 SD higher in HDL-C per relative abundance (log10) increase in Acidaminococcus. 
